Trial
NCT06007651
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Dyslipidemias
Intervention
LY3885125
Why stopped
Participants were not dosed in Part B as per the protocol.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-13